Charged Alpha Stock Encyclopedia

United Airlines (UAL) Q2 2026 — United Airlines (UAL) reported a strong Q2 2026: revenue up 16% YoY to $17.7B, adjusted EPS $1.99 (beat $1.91), unit revenue (TRASM) +12.1%, with premium revenue +16%, loyalty +11% and cargo +23%. Most notably, it RAISED full-year 2026 adjusted EPS guidance to $9.00-$11.00 despite absorbing nearly $6B more fuel cost. The stock (~$119, ~14% off its $139 high, ~12x forward) barely moved. The Street is bullish — a Buy consensus, target ~$155 (+30%).

Airlines have destroyed shareholder value for decades — brutally cyclical, capital-hungry, at the mercy of fuel and labor. So is United, the best-run of the group, the exception? Its Q2 2026 was genuinely strong: revenue +16% to $17.7B, adjusted EPS $1.99 (beat), unit revenue +12%, and — the key point — it RAISED full-year guidance to $9-11 adjusted EPS while absorbing a nearly $6B fuel-cost increase. That's pricing power beating input costs. The engine is its premium strategy: premium-cabin revenue +16%, MileagePlus loyalty +11% (the closest thing to an airline moat), and a hard-to-replicate international network. The industry has consolidated to four disciplined carriers, and travelers are trading up to premium — right where United is strongest. At ~12x it's cheap, but we discount airline earnings for cyclicality: our cycle-adjusted fair value lands near $140 (vs $119), below the Street's $155. Our call: BUY, 3/5 — a cheap, well-run airline in a better-structured industry. Own it as a value bet; buy weakness, and watch the demand data, because in airlines the cycle is everything. Not financial advice.

THE CALL: BUY (3/5, CHEAP AND EXECUTING — RAISED GUIDANCE THROUGH A FUEL SHOCK) — base-case value ~$140 vs ~$119 today.

What to watch: unit revenue and premium demand holding up (pricing power intact); the risk that breaks it is any sign travel demand is rolling over or a fuel spike it can't pass through — buy weakness rather than chase strength

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Cintas (CTAS) Q4 FY2026 — Cintas (CTAS), the uniform-rental and facility-services compounder, reported fiscal Q4 2026: revenue up ~7% to $2.9B, adjusted EPS $1.29 (beat $1.24), operating margin over 23%. The stock popped ~7%. It's a wide-moat, recurring-revenue machine (route density, ~23% margins, cross-selling first aid/safety and fire protection) — one of the best-performing stocks of the past few decades. But near ~$206 (~9% off its $227 high) it trades at ~40x earnings for ~8-10% growth. The Street is split — a Hold consensus, target ~$231.

Cintas is one of the most boring businesses in the market — renting uniforms and supplying mats, first-aid kits and fire extinguishers — and one of the best-performing stocks of the last few decades. It just beat again (fiscal Q4 revenue +7% to $2.9B, adjusted EPS $1.29, ~23% operating margin) and popped ~7%. The moat is route density: once its trucks serve a neighborhood, the next customer is nearly free, driving best-in-class margins and relentless, recurring-revenue compounding via new customers, cross-selling, and price. There's no turnaround to debate — the only question is the price. At ~40x earnings for ~8-10% growth, it's priced for perfection: our owner-earnings work lands fair value near $203, essentially right at the ~$206 price, with no margin of safety. Our call: HOLD, 3/5 — an elite compounder we'd love to own cheaper. Own it if you have it; wait for a market pullback toward the mid-$170s if you don't. Not financial advice.

THE CALL: HOLD (3/5, AN ELITE COMPOUNDER, PRICED FOR PERFECTION) — base-case value ~$205 vs ~$206 today.

What to watch: a broad market pullback that takes it toward the mid-$170s (a rare cheap entry), or growth reaccelerating above 10% (via cross-selling or M&A) that lets the ~40x multiple grow into itself; the risk is a de-rating from that multiple on any growth wobble

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Elevance Health (ELV) Q2 2026 — Elevance Health (ELV), one of the largest U.S. health insurers (~46M members, formerly Anthem), reported Q2 2026 adjusted EPS of $7.45, crushing the $6.18 estimate (helped by Carelon pharmacy) — but that was down from $8.84 a year ago, and the stock FELL. Despite the beat, it RAISED full-year adjusted EPS guidance to at least $27.00. The problem: a rising medical loss ratio (surging medical costs) has earnings falling YoY, and the market doubts the beat is sustainable. The stock (~$373, ~14x forward) is ~15% off its $436 high, off a $274 low.

Here's a puzzle: Elevance Health (formerly Anthem) — a ~46-million-member health-insurance giant — just beat earnings AND raised its full-year guidance to at least $27/share, and the stock fell anyway. Why? Because underneath the beat is a rising medical loss ratio: members are using more care than the company priced for, so margins are compressing and adjusted EPS ($7.45) is down sharply from $8.84 a year ago. The beat was against a lowered bar, and the market doubts it's sustainable. It's a sector-wide storm (utilization, Medicare Advantage, Medicaid) hitting all managed care. The bull case: a scaled, essential insurer at ~14x (a cyclical trough), with a growing fee-based Carelon arm, that just raised guidance — the Street sees ~17% upside ($438 target) if costs peak. The bear case: earnings are falling and the MLR is still rising. Our owner-earnings work lands near $390 (vs $373) — modest upside if costs normalize. Our call: HOLD, 3/5 — cheap and raising guidance, but medical costs are the swing. Watch the MLR; add near the lows. Not financial advice.

THE CALL: HOLD (3/5, CHEAP AND RAISING GUIDANCE, BUT MEDICAL COSTS ARE THE SWING) — base-case value ~$390 vs ~$373 today.

What to watch: the medical loss ratio (MLR) flattening and then falling — the single number that proves costs have peaked and the earnings recovery is real; the risk is a future guidance cut if costs keep rising

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Johnson & Johnson (JNJ) Q2 2026 — Johnson & Johnson (JNJ) reported a clean Q2 2026 beat: sales +6.6% to $25.3B, adjusted EPS $2.90 (+4.7%, ahead of estimates), with Innovative Medicine (pharma) sales +6.8% out-growing the patent cliffs. It RAISED full-year guidance to ~$101.1B sales (+7.3%) and $11.68 adjusted EPS (+8.2%) — on track to cross $100B in annual revenue for the first time in its 140-year history. The AAA-rated Dividend King (~250) has recovered strongly off its ~$162 low to ~7% below its ~$269 high, and rose on the print.

Johnson & Johnson is the ultimate healthcare fortress — a diversified, AAA-rated giant (one of only a handful on earth) with two engines (Innovative Medicine pharma + MedTech devices) and a 60+ year dividend-increase streak. In Q2 2026 it beat (sales +6.6% to $25.3B, adjusted EPS $2.90) and RAISED guidance to ~$101.1B sales and $11.68 adjusted EPS — crossing $100B in annual revenue for the first time in 140 years. The pharma engine (+6.8%) is out-growing the Stelara-style patent cliffs, which is the whole long-term debate. The overhangs are talc litigation and drug-pricing policy, and after recovering near its highs it trades at ~21x forward for ~8% growth — full, not cheap. Our owner-earnings work lands near $260 (vs ~$250), below the Street's ~$272. Our call: HOLD, 3/5 — a beat-and-raise from a fortress at a fair price; own it for resilience and the ~3% AAA-backed dividend, add on talc-driven dips. Not financial advice.

THE CALL: HOLD (3/5, A HEALTHCARE FORTRESS, BEAT AND RAISED, AT A FAIR PRICE) — base-case value ~$260 vs ~$250 today.

What to watch: a clean, capped talc-litigation settlement (removing the biggest overhang), continued pharma-pipeline launches out-growing the Stelara patent cliff, and talc-headline dips toward the low $230s as add points

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

ASML Holding (ASML) Q2 2026 — ASML Holding (ASML) — the sole maker of EUV lithography machines, essential to every advanced AI chip — reported a clean Q2 2026 beat: net sales €9.3B, a 54.0% gross margin (above guidance), and €2.9B net income (EPS €7.59). It RAISED its 2026 outlook to €43-45B sales at 54-56% gross margin, guided Q3 to €11-12B, and said it has substantially all the orders it needs for 2027 (while adding ~30% EUV capacity). It bought back €1.1B of stock. Yet the ADR (~$1,785, ~11% off its ~$2,000 high after more than doubling off its low) slipped — an expectations/valuation story, not a fundamentals one.

ASML is the closest thing to a true monopoly in technology: the only company on earth that makes EUV lithography machines, the tools every leading-edge AI chip is built on. In Q2 2026 it beat (€9.3B sales, 54% gross margin, €2.9B net income) AND raised its full-year outlook (€43-45B sales, 54-56% GM) — yet the stock fell, because after more than doubling off its low it's priced for perfection at ~40x forward earnings. The order book answers the cycle worry: 2027 is essentially sold out, ASML is adding ~30% more EUV capacity, and High-NA is ramping (Intel in production). Demand is the AI supercycle — logic and DRAM memory both flow through ASML's one toll booth. It's a cash machine too (€1.1B buyback in the quarter, growing dividend). Our owner-earnings work lands near $2,050 (vs $1,785), below the Street's ~$2,300 but real upside. Our call: BUY, 3/5 — the AI supercycle's one true monopoly, at a fair-not-cheap price; add on cyclical dips. Not financial advice.

THE CALL: BUY (3/5, THE AI SUPERCYCLE'S ONE TRUE MONOPOLY) — base-case value ~$2050 vs ~$1785 today.

What to watch: the 2028 order book filling in the way 2027 already has (pushing the cycle worry further out), continued High-NA EUV adoption, and using cyclical or China-headline pullbacks toward the mid-$1,600s to add

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Conagra Brands (CAG) Q4 FY2026 — Conagra Brands (CAG) reported fiscal Q4 2026: net sales +3.6% to $2.9B (organic flat), adjusted EPS $0.47 (a penny beat), but a GAAP loss of $3.37/share from a ~$1.6B non-cash brand impairment. The big news: Conagra cut its annual dividend in half, to $0.70 from $1.40, to fund reinvestment (+$125M capex, +$40M brand) and deleverage toward 3.0x. It guided FY2027 adjusted EPS to $1.40-$1.50, below the ~$1.70 Street, with organic sales -1% to -3%. The stock (~$14.48, near its 52-week low) rose on the reset.

Conagra just did something painful — it cut its dividend in half, from $1.40 to $0.70 — and the stock went up. That reaction is the whole story. CAG is cheap (~10x next year's earnings), near its 52-week low, in the same beaten-down packaged-food group as General Mills and Kraft Heinz. Alongside results it also took a ~$1.6B brand impairment and guided FY2027 below the Street (adjusted EPS $1.40-$1.50 vs ~$1.70; organic sales -1% to -3%). But the cut isn't distress — it frees cash to reinvest (+$125M capex, +$40M brand) and pay down debt toward 3.0x, and a ~12% free-cash-flow yield says a lot of bad news was already priced in. The new ~4.8% dividend is now well-covered. Our owner-earnings work lands near $15 (just above the $14.48 price) whether the business slowly declines or merely stabilizes. Our call: HOLD, 3/5 — cheap and resetting, but still shrinking. Collect the yield, watch organic sales; demand a lower price for real upside. Not financial advice.

THE CALL: HOLD (3/5, CHEAP AND RESETTING, BUT STILL SHRINKING) — base-case value ~$15 vs ~$14.48 today.

What to watch: organic sales declines flattening out (the single best tell that the erosion has stopped), successful deleveraging toward the 3.0x net-debt target, and evidence the snacking bright spot is offsetting frozen weakness

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Sify Technologies (SIFY) Q1 FY2027 — Sify Technologies (SIFY) — an Indian ICT company pivoting hard into data centers for the AI/cloud buildout — reported fiscal Q1 2027 revenue up 15% YoY to INR 12,352M (~$149M), adjusted EBITDA up 42% to ~INR 3,005M (~$36M), and swung to a small net profit (~INR 65M) versus a year-ago loss. Data centers are now 42% of revenue. But quarterly capex (~INR 6,708M / ~$81M) was more than 2x EBITDA, net debt is ~$563M (~3.9x EBITDA), and the ADR has tripled off its 52-week low (~$4.84) to ~$14.69.

Sify Technologies is one of the purest ways to bet on India's data-center and AI-infrastructure boom — and its fiscal Q1 2027 marked a real inflection: revenue up 15%, adjusted EBITDA up 42%, and a first net profit after years of losses, with data centers now the biggest segment at 42% of revenue. The catch is the balance sheet. To build all that capacity, Sify spent ~$81M of capex in the quarter — more than double its ~$36M of EBITDA — leaving it deeply free-cash-flow negative and carrying ~$563M of net debt (~3.9x EBITDA). At ~$14.69 (a triple off its ~$4.84 low), it trades near 14x EV/EBITDA — reasonable for 42% growth, but that EV already includes the debt. Our call: HOLD, 3/5. Fair value ~$14, roughly today's price — a genuine inflection and a huge theme, offset by heavy leverage and cash burn. Size it small; watch for deleveraging. Not financial advice.

THE CALL: HOLD (3/5, A REAL DATA-CENTER STORY, ON A LEVERAGED BALANCE SHEET) — base-case value ~$14 vs ~$14.69 today.

What to watch: deleveraging — net-debt-to-EBITDA falling as data-center capacity fills and EBITDA compounds — plus a free-cash-flow turn once capex stops dwarfing operating cash flow

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Winmark Corporation (WINA) Q2 2026 — Winmark (WINA) — the franchisor behind resale chains Plato's Closet, Once Upon a Child, Play It Again Sports and Style Encore — reported fiscal Q2 2026 revenue up ~7.6% to $22.0M at a ~62% operating margin, with EPS ~$2.81 (roughly flat YoY and a touch light of a thin estimate). The stock rose anyway. It's an asset-light, counter-cyclical royalty machine that returns essentially all its cash (book equity is negative by design). At ~$398 (~25% off its $527 high, ~35x TTM EPS), our DCF work lands below the price.

How does a company earn a 62% operating margin selling other people's used clothes? Winmark isn't the store — it's the franchisor, collecting a royalty on everything its resale franchisees sell. Almost no capital, almost no inventory, and demand that actually rises in a downturn (more people buy and sell secondhand). It's one of the highest-quality little compounders around, and it has returned so much cash via buybacks and special dividends that its book equity is negative by design. Q2 revenue grew ~7.6% to $22M; EPS ~$2.81 was flat YoY and light of a thin estimate, but the market shrugged and the stock rose. The catch is price: at ~$398 (~35x earnings, 25% off its $527 high), every cut of our discounted-cash-flow model lands below the price — base case ~$273, quality-adjusted ~$365. Our call: HOLD, 3/5. A wonderful business we'd love to own cheaper. Not financial advice.

THE CALL: HOLD (3/5, A WONDERFUL BUSINESS AT A DEMANDING PRICE) — base-case value ~$365 vs ~$398 today.

What to watch: a pullback toward the 52-week low near $340 (where price meets the cash flows), EPS growth reaccelerating into the high single digits, and continued royalty/franchise growth with the relentless buyback shrinking the float

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Frequency Electronics (FEIM) Q4 FY2026 — Frequency Electronics (FEIM) — a niche maker of atomic clocks and precision timing for satellites, missiles and secure military comms — reported an ugly fiscal Q4: gross margin collapsed to ~1% (vs a normal ~30%) and EPS came in at -$0.50 versus a +$0.27 estimate, a big miss, on a $3.8M Elcom inventory write-down and pre-revenue investment. Strip the one-offs and adjusted gross margin was ~36%. Backlog hit a record $111M, and management reaffirmed a $150M FY2029 revenue target. After a run from ~$20 to $80, the stock trades near $51 — above Wall Street's ~$44 target.

How does a company post a 1% gross margin and a record order book in the same quarter? Frequency Electronics makes the ultra-precise atomic clocks and oscillators that keep satellites, missiles and military radios in sync — a tiny, hard-to-replace niche. Its GAAP Q4 looked like a disaster (EPS -$0.50 vs +$0.27 expected, gross margin ~1%), but that was mostly a one-time $3.8M inventory write-down plus pre-revenue investment; adjusted gross margin was ~36%. Backlog is at a record $111M and management targets $150M revenue at 50% gross margins by FY2029. The catch: after quadrupling to $80 and settling near $51, the stock trades at ~8x sales — above even Wall Street's ~$44 target — with cash down to $1.6M. Our call: HOLD, 3/5. Fair value ~$44, modestly below the price. A wonderful little niche that already believes its own best-case future. Not financial advice.

THE CALL: HOLD (3/5, A REAL STORY, BUT THE PRICE ALREADY BELIEVES IT) — base-case value ~$44 vs ~$51.51 today.

What to watch: gross margin recovering back toward 30%+ over one or two clean quarters (proving the Q4 charge was one-time), the record $111M backlog converting to revenue without fresh write-downs, and a pullback toward or below the ~$44 Street target

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

BitMine Immersion Technologies (BMNR) Q3 FY2026 — BitMine Immersion (BMNR), the largest corporate holder of Ethereum on earth (~5% of all ETH), trades at roughly a 13% discount to the value of its own coins — you buy a dollar of Ethereum for about 87 cents. But it carries an ~$8.2B unrealized loss from buying ETH near the top, and funds itself with 12%-cost preferred to earn a 2.7% staking yield. The stock is down ~88% from its 2025 hype peak of $135, last around $15.79.

How can a company's Ethereum be worth more than the entire company? BitMine holds about $10.5B of ETH (plus ~$0.8B cash) — roughly $11.3B of net assets — against a ~$9.5B market cap. That's a real ~13% discount to NAV, and per-share ETH is still rising (+18% YoY, 9.57 ETH per 1,000 shares), so the dilution has been accretive. But there's an eight-billion-dollar catch: management paid ~$19B for a stake now worth ~$11B, and pays a 12% cost of capital to earn under 3%. This isn't a business — it's leveraged Ethereum with a management fee. Our call: HOLD, 3/5. Fair value ≈ NAV, near $18. Own the discount only if you actually want to own the Ethereum. Not financial advice.

THE CALL: HOLD (3/5, A DOLLAR OF ETH FOR 87 CENTS, BUT IT IS JUST ETH) — base-case value ~$18 vs ~$15.79 today.

What to watch: the mNAV discount widening below 0.8x (a wider margin of safety), a shift from issuing stock to buying it back below NAV (the accretive move), and above all the direction of Ethereum itself

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.